Survival of stage III non-seminoma testis cancer patients versus simulated controls, according to race/ethnicity

IF 1.8 3区医学 Q3 UROLOGY & NEPHROLOGY

International Journal of Urology Pub Date : 2024-07-05 DOI:10.1111/iju.15532

Simone Morra, Cristina Cano Garcia, Mattia Luca Piccinelli, Stefano Tappero, Francesco Barletta, Reha-Baris Incesu, Lukas Scheipner, Andrea Baudo, Zhe Tian, Mario de Angelis, Vincenzo Mirone, Gianluigi Califano, Giuseppe Celentano, Fred Saad, Shahrokh F. Shariat, Felix K. H. Chun, Ottavio de Cobelli, Gennaro Musi, Carlo Terrone, Alberto Briganti, Derya Tilki, Sascha Ahyai, Luca Carmignani, Nicola Longo, Pierre I. Karakiewicz

{"title":"Survival of stage III non-seminoma testis cancer patients versus simulated controls, according to race/ethnicity","authors":"Simone Morra, Cristina Cano Garcia, Mattia Luca Piccinelli, Stefano Tappero, Francesco Barletta, Reha-Baris Incesu, Lukas Scheipner, Andrea Baudo, Zhe Tian, Mario de Angelis, Vincenzo Mirone, Gianluigi Califano, Giuseppe Celentano, Fred Saad, Shahrokh F. Shariat, Felix K. H. Chun, Ottavio de Cobelli, Gennaro Musi, Carlo Terrone, Alberto Briganti, Derya Tilki, Sascha Ahyai, Luca Carmignani, Nicola Longo, Pierre I. Karakiewicz","doi":"10.1111/iju.15532","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Background</h3>\n \n <p>It is unknown whether 5-year overall survival (OS) differs and to what extent between the American Joint Committee on Cancer stage III non-seminoma testicular germ cell tumor (NS-TGCT) patients and simulated age-matched male population-based controls, according to race/ethnicity groups.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We identified newly diagnosed (2004–2014) stage III NS-TGCT patients within the Surveillance Epidemiology and End Results database 2004–2019. For each case, we simulated an age-matched male control (Monte Carlo simulation), relying on Social Security Administration (SSA) Life Tables with 5 years of follow-up. We compared OS rates between stage III NS-TGCT patients and simulated age-matched male population-based controls, according to race/ethnicity groups (Caucasian, Hispanic, Asian/Pacific Islander and African American). Both, cancer-specific mortality (CSM) and other-cause mortality (OCM) were computed.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of 2054 stage III NS-TGCT patients, 60% were Caucasians versus 33% Hispanics versus 4% Asians/Pacific Islanders versus 3% African Americans. The 5-year OS difference between stage III NS-TGCT patients versus simulated age-matched male population-based controls was highest in Asians/Pacific Islanders (64 vs. 99%, Δ = 35%), followed by African Americans (66 vs. 97%, Δ = 31%), Hispanics (72 vs. 99%, Δ = 27%), and Caucasians (76 vs. 98%, Δ = 22%). The 5-year CSM rate was highest in Asians/Pacific Islanders (32%), followed by African Americans (26%), Hispanics (25%), and Caucasians (20%). The 5-year OCM rate was highest in African Americans (8%), followed by Caucasians (4%), Asians/Pacific Islanders (4%), and Hispanics (2%).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Relative to SSA Life Tables, the highest 5-year OS disadvantage applied to stage III NS-TGCT Asian/Pacific Islander race/ethnicity group, followed by African American, Hispanic and Caucasian, in that order.</p>\n </section>\n </div>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"31 10","pages":"1137-1143"},"PeriodicalIF":1.8000,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/iju.15532","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

It is unknown whether 5-year overall survival (OS) differs and to what extent between the American Joint Committee on Cancer stage III non-seminoma testicular germ cell tumor (NS-TGCT) patients and simulated age-matched male population-based controls, according to race/ethnicity groups.

Methods

We identified newly diagnosed (2004–2014) stage III NS-TGCT patients within the Surveillance Epidemiology and End Results database 2004–2019. For each case, we simulated an age-matched male control (Monte Carlo simulation), relying on Social Security Administration (SSA) Life Tables with 5 years of follow-up. We compared OS rates between stage III NS-TGCT patients and simulated age-matched male population-based controls, according to race/ethnicity groups (Caucasian, Hispanic, Asian/Pacific Islander and African American). Both, cancer-specific mortality (CSM) and other-cause mortality (OCM) were computed.

Results

Of 2054 stage III NS-TGCT patients, 60% were Caucasians versus 33% Hispanics versus 4% Asians/Pacific Islanders versus 3% African Americans. The 5-year OS difference between stage III NS-TGCT patients versus simulated age-matched male population-based controls was highest in Asians/Pacific Islanders (64 vs. 99%, Δ = 35%), followed by African Americans (66 vs. 97%, Δ = 31%), Hispanics (72 vs. 99%, Δ = 27%), and Caucasians (76 vs. 98%, Δ = 22%). The 5-year CSM rate was highest in Asians/Pacific Islanders (32%), followed by African Americans (26%), Hispanics (25%), and Caucasians (20%). The 5-year OCM rate was highest in African Americans (8%), followed by Caucasians (4%), Asians/Pacific Islanders (4%), and Hispanics (2%).

Conclusion

Relative to SSA Life Tables, the highest 5-year OS disadvantage applied to stage III NS-TGCT Asian/Pacific Islander race/ethnicity group, followed by African American, Hispanic and Caucasian, in that order.

查看原文本刊更多论文

根据种族/族裔划分的 III 期非睾丸癌患者与模拟对照组的生存率。

背景：美国癌症联合委员会III期非精原细胞瘤睾丸生殖细胞瘤（NS-TGCT）患者与模拟年龄匹配男性人群对照组之间的5年总生存率（OS）是否存在差异，以及差异程度如何，目前尚不清楚：我们在 2004-2019 年监测流行病学和最终结果数据库中确定了新诊断的（2004-2014 年）III 期 NS-TGCT 患者。对于每个病例，我们都模拟了一个年龄匹配的男性对照（蒙特卡罗模拟），依据的是社会保障局（SSA）随访 5 年的生命表。我们根据种族/族裔群体（白种人、西班牙裔、亚太裔和非裔美国人）比较了III期NS-TGCT患者和模拟的年龄匹配男性对照组的OS率。计算了癌症特异性死亡率（CSM）和其他原因死亡率（OCM）：在2054例III期NS-TGCT患者中，60%为白种人，33%为西班牙裔人，4%为亚洲/太平洋岛民，3%为非裔美国人。III期NS-TGCT患者与模拟年龄匹配男性人群对照组的5年OS差异在亚洲人/太平洋岛民中最高（64 vs. 99%，Δ = 35%），其次是非裔美国人（66 vs. 97%，Δ = 31%）、西班牙裔美国人（72 vs. 99%，Δ = 27%）和白种人（76 vs. 98%，Δ = 22%）。亚裔/太平洋岛民的 5 年 CSM 患病率最高（32%），其次是非裔美国人（26%）、西班牙裔美国人（25%）和白种人（20%）。非裔美国人的 5 年 OCM 率最高（8%），其次是白种人（4%）、亚裔/太平洋岛民（4%）和西班牙裔（2%）：结论：相对于 SSA 生命表，NS-TGCT III 期亚太裔种族/民族群体的 5 年 OS 劣势最大，其次依次是非裔美国人、西班牙裔和白种人。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Urology 医学-泌尿学与肾脏学

CiteScore

4.70

自引率

11.50%

发文量

340

审稿时长

3 months

期刊介绍： International Journal of Urology is the official English language journal of the Japanese Urological Association, publishing articles of scientific excellence in urology. Submissions of papers from all countries are considered for publication. All manuscripts are subject to peer review and are judged on the basis of their contribution of original data and ideas or interpretation.